Watch What You Eat: A PhRMA Marketing Code Q&A
This article was originally published in RPM Report
Executive Summary
Revisions to PhRMA’s 2002 voluntary marketing code that go into effect in January delve into the specifi cs of what pharma sales reps are allowed to do and what they should avoid when interacting with health professionals.
You may also be interested in...
DTC User Fees Shot Down; Advertisers Face More Perilous Future
The good news for advertisers: FDA will have more resources for pre-review of ads in 2008, funded by the taxpayers. The bad news: what happens in 2009?
Off-Label Sales in Jeopardy: Rx Industry Fights for Clarity
Off-label use of prescription drugs is worth billions of dollars to manufacturers, but no one likes to talk about it. Defensiveness is understandable, with scores of companies under investigations for allegedly promoting those uses illegally. The truth is that no one is very happy about the current state of off-label medication use, but calls for change are contradictory and tough to resolve.
DTC Loses Powerful Friends, Will PhRMA Bring Them Back?
Direct-to-consumer advertising is being blamed in large part for the pharmaceutical industry's eroding reputation. Some of the industry's oldest friends in Congress are proposing moratoriums on DTC ads. PhRMA's DTC guidelines may have mollified Congress and FDA for now. However, with the hundreds of billions of dollars lined up for the Medicare drug benefit, CMS could be the newest player in restricting DTC.